High dose aflibercept may be promising for treatment of age-related macular degeneration
1. Aflibercept 8 mg was non-inferior to 2 mg for best-corrected visual acuity at 48 weeks. 2. Ocular adverse events ...
1. Aflibercept 8 mg was non-inferior to 2 mg for best-corrected visual acuity at 48 weeks. 2. Ocular adverse events ...
1. Avacincaptad pegol significantly slowed geographic atrophy over 12 months. 2. Exudative macular neovascularization was comparable among treatment groups. Evidence ...
1. In a cohort of about 500 eyes with primary open-angle glaucoma (POAG), higher smoking intensity in pack-years was significantly ...
1. In a phase 3a randomized trial comparing intravitreal brolucizumab to aflibercept for refractory neovascular age-related macular degeneration (nAMD), there ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.